Literature DB >> 20483764

TGF-beta-induced myelin peptide-specific regulatory T cells mediate antigen-specific suppression of induction of experimental autoimmune encephalomyelitis.

Hong Zhang1, Joseph R Podojil, Judy Chang, Xunrong Luo, Stephen D Miller.   

Abstract

The low number of natural regulatory T cells (nTregs) in the circulation specific for a particular Ag and concerns about the bystander suppressive capacity of expanded nTregs presents a major clinical challenge for nTreg-based therapeutic treatment of autoimmune diseases. In the current study, we demonstrate that naive CD4+CD25-Foxp3- T cells specific for the myelin proteolipid protein (PLP)139-151 peptide can be converted into CD25+Foxp3+ induced Treg cells (iTregs) when stimulated in the presence of TGF-beta, retinoic acid, and IL-2. These PLP139-151-specific iTregs (139-iTregs) have a phenotype similar to nTregs, but additionally express an intermediate level of CD62L and a high level of CD103. Upon transfer into SJL/J mice, 139-iTregs undergo Ag-driven proliferation and are effective at suppressing induction of experimental autoimmune encephalomyelitis induced by the cognate PLP139-151 peptide, but not PLP178-191 or a mixture of the two peptides. Furthermore, 139-iTregs inhibit delayed-type hypersensitivity responses to PLP139-151, but not PLP178-191, myelin oligodendrocyte glycoprotein (MOG)35-55, or OVA323-339 in mice primed with a mixture of PLP139-151 and the other respective peptides. Additionally, 139-iTregs suppress the proliferation and activation of PLP139-151-, but not MOG35-55-specific CD4+ T cells in SJL/B6 F1 mice primed with a combination of PLP139-151 and MOG35-55. These findings suggest that Ag-specific iTregs are amplified in vivo when exposed to cognate Ag under inflammatory conditions, and these activated iTregs suppress CD4+ responder T cells in an Ag-specific manner.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20483764      PMCID: PMC2882517          DOI: 10.4049/jimmunol.0904044

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  39 in total

1.  Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes.

Authors:  Olivier Joffre; Nathalie Gorsse; Paola Romagnoli; Denis Hudrisier; Joost P M van Meerwijk
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

2.  Homing to suppress: address codes for Treg migration.

Authors:  Jochen Huehn; Alf Hamann
Journal:  Trends Immunol       Date:  2005-10-21       Impact factor: 16.687

3.  CD4+CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells.

Authors:  Richard J DiPaolo; Deborah D Glass; Karen E Bijwaard; Ethan M Shevach
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

Review 4.  CNS dendritic cells: critical participants in CNS inflammation?

Authors:  Eileen J McMahon; Samantha L Bailey; Stephen D Miller
Journal:  Neurochem Int       Date:  2006-05-30       Impact factor: 3.921

5.  Adaptive islet-specific regulatory CD4 T cells control autoimmune diabetes and mediate the disappearance of pathogenic Th1 cells in vivo.

Authors:  Sarah E Weber; Judith Harbertson; Elana Godebu; Guthrie A Mros; Ryan C Padrick; Bryan D Carson; Steven F Ziegler; Linda M Bradley
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

6.  Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice.

Authors:  Kristin V Tarbell; Lucine Petit; Xiaopan Zuo; Priscilla Toy; Xunrong Luo; Amina Mqadmi; Hua Yang; Manikkam Suthanthiran; Svetlana Mojsov; Ralph M Steinman
Journal:  J Exp Med       Date:  2007-01-08       Impact factor: 14.307

7.  Single cell analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes.

Authors:  Shannon M Pop; Carmen P Wong; Donna A Culton; Stephen H Clarke; Roland Tisch
Journal:  J Exp Med       Date:  2005-04-18       Impact factor: 14.307

8.  Developmental stage, phenotype, and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells.

Authors:  Jochen Huehn; Kerstin Siegmund; Joachim C U Lehmann; Christiane Siewert; Uta Haubold; Markus Feuerer; Gudrun F Debes; Joerg Lauber; Oliver Frey; Grzegorz K Przybylski; Uwe Niesner; Maurus de la Rosa; Christian A Schmidt; Rolf Bräuer; Jan Buer; Alexander Scheffold; Alf Hamann
Journal:  J Exp Med       Date:  2004-02-02       Impact factor: 14.307

9.  The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells.

Authors:  S D Miller; R P Wetzig; H N Claman
Journal:  J Exp Med       Date:  1979-03-01       Impact factor: 14.307

10.  CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes.

Authors:  Kristin V Tarbell; Sayuri Yamazaki; Kara Olson; Priscilla Toy; Ralph M Steinman
Journal:  J Exp Med       Date:  2004-06-07       Impact factor: 14.307

View more
  27 in total

1.  HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease.

Authors:  Jun Li; Jessica Heinrichs; Kelley Haarberg; Kenrick Semple; Anandharaman Veerapathran; Chen Liu; Claudio Anasetti; Xue-Zhong Yu
Journal:  J Immunol       Date:  2015-06-05       Impact factor: 5.422

2.  Peripherally Induced Tolerance Depends on Peripheral Regulatory T Cells That Require Hopx To Inhibit Intrinsic IL-2 Expression.

Authors:  Andrew Jones; Adeleye Opejin; Jacob G Henderson; Cindy Gross; Rajan Jain; Jonathan A Epstein; Richard A Flavell; Daniel Hawiger
Journal:  J Immunol       Date:  2015-07-13       Impact factor: 5.422

3.  Regulatory T cells in CNS injury: the simple, the complex and the confused.

Authors:  James T Walsh; Jonathan Kipnis
Journal:  Trends Mol Med       Date:  2011-07-07       Impact factor: 11.951

Review 4.  The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.

Authors:  Andrew P Robinson; Christopher T Harp; Avertano Noronha; Stephen D Miller
Journal:  Handb Clin Neurol       Date:  2014

5.  Sequential monitoring and stability of ex vivo-expanded autologous and nonautologous regulatory T cells following infusion in nonhuman primates.

Authors:  H Zhang; H Guo; L Lu; A F Zahorchak; R W Wiseman; G Raimondi; D K C Cooper; M B Ezzelarab; A W Thomson
Journal:  Am J Transplant       Date:  2015-03-17       Impact factor: 8.086

6.  High self-reactivity drives T-bet and potentiates Treg function in tissue-specific autoimmunity.

Authors:  Maran L Sprouse; Marissa A Scavuzzo; Samuel Blum; Ivan Shevchenko; Thomas Lee; George Makedonas; Malgorzata Borowiak; Matthew L Bettini; Maria Bettini
Journal:  JCI Insight       Date:  2018-01-25

7.  ILDR2-Fc Is a Novel Regulator of Immune Homeostasis and Inducer of Antigen-Specific Immune Tolerance.

Authors:  Joseph R Podojil; Iris Hecht; Ming-Yi Chiang; Ilan Vaknin; Inbal Barbiro; Amit Novik; Eyal Neria; Galit Rotman; Stephen D Miller
Journal:  J Immunol       Date:  2018-02-05       Impact factor: 5.422

8.  Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells.

Authors:  Suchitra Prasad; Tobias Neef; Dan Xu; Joseph R Podojil; Daniel R Getts; Lonnie D Shea; Stephen D Miller
Journal:  J Autoimmun       Date:  2017-12-16       Impact factor: 7.094

9.  Development of experimental autoimmune encephalomyelitis critically depends on CD137 ligand signaling.

Authors:  Julia M Martínez Gómez; J Ludovic Croxford; Kim Pin Yeo; Véronique Angeli; Herbert Schwarz; Stephan Gasser
Journal:  J Neurosci       Date:  2012-12-12       Impact factor: 6.167

10.  Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice.

Authors:  Kenrick Semple; Yu Yu; Dapeng Wang; Claudio Anasetti; Xue-Zhong Yu
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-09       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.